Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis

Abstract

BACKGROUND: Once-daily injections of parathyroid hormone or its amino-terminal fragments increase bone formation and bone mass without causing hypercalcemia, but their effects on fractures are unknown. METHODS: We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observation, 21 months) and performed serial measurements of bone mass by dual-energy x-ray absorptiometry. RESULTS: New vertebral fractures occurred in 14 percent of the women in the placebo group and in 5 percent and 4 percent, respectively, of the women in the 20-microg and 40-microg parathyroid hormone groups; the respective relative risks of fracture in the 20-microg and 40-microg groups, as compared with the placebo group, were 0.35 and 0.31 (95 percent confidence intervals, 0.22 to 0.55 and 0.19 to 0.50). New nonvertebral fragility fractures occurred in 6 percent of the women in the placebo group and in 3 percent of those in each parathyroid hormone group (relative risk, 0.47 and 0.46, respectively [95 percent confidence intervals, 0.25 to 0.88 and 0.25 to 0.861). As compared with placebo, the 20-microg and 40-microg doses of parathyroid hormone increased bone mineral density by 9 and 13 more percentage points in the lumbar spine and by 3 and 6 more percentage points in the femoral neck; the 40-microg dose decreased bone mineral density at the shaft of the radius by 2 more percentage points. Both doses increased total-body bone mineral by 2 to 4 more percentage points than did placebo. Parathyroid hormone had only minor side effects (occasional nausea and headache). CONCLUSIONS: Treatment of postmenopausal osteoporosis with parathyroid hormone (1-34) decreases the risk of vertebral and nonvertebral fractures; increases vertebral, femoral, and total-body bone mineral density; and is well tolerated. The 40-microg dose increased bone mineral density more than the 20-microg dose but had similar effects on the risk of fracture and was more likely to have side effects.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm200105103441904

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 29 references

Research works printed but not linked: 2

  1. Dempster DW, 1993, Endocr Rev, 14, 690
  2. 10.1002/(sici)1097-0258(19970830)16:16<1889::aid-sim607>3.0.co;2-v · doi:10.1002/(sici)1097-0258(19970830)16:16<1889::aid-sim607>3.0.co;2-v

Cited by

See all 4,602

Metadata

Authors
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., Wang, O., Mellström, D., Oefjord, E. S., Marcinowska-Suchowierska, E., Salmi, J., Mulder, H., Halse, J., Sawicki, A. Z., & Mitlak, B. H.
Affiliations
  • Harvard University (US)
  • University of California, San Francisco (US)
  • The University of Western Australia (AU)
  • Eli Lilly (United States) (US)
  • University of Liège (BE)
  • St Joseph's Health Care (CA)
Venue
New England Journal of Medicine
Published
2001-05-10
Volume
344
Issue
19
Pages
1434-1441
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2335178464
Cited by
4,602
References
29
Citations by year
2026: 116 · 2025: 136 · 2024: 133 · 2023: 124 · 2022: 148 · 2021: 153 · 2020: 168 · 2019: 165 · 2018: 203 · 2017: 189 · 2016: 172 · 2015: 212 · 2014: 197 · 2013: 205 · 2012: 182
FWCI
174.97
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
  • ORBi (University of Liège) (submittedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
parathyroid hormone (1-34), postmenopausal osteoporosis, vertebral fractures, bone mineral density, bone formation, fracture risk reduction, lumbar spine, femoral neck, dose comparison, treatment tolerability, hypercalcemia, subcutaneous injection, women's health, osteoporosis treatment
MeSH terms
Dose-Response Relationship, Drug, Female, Femur, Humans, Injections, Subcutaneous, Lumbar Vertebrae, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Teriparatide, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. https://app.cochat.ai/papers/10.1056/nejm200105103441904
The paper
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., Wang, O., Mellström, D., Oefjord, E. S., Marcinowska-Suchowierska, E., Salmi, J., Mulder, H., Halse, J., Sawicki, A. Z., & Mitlak, B. H. (2001). Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. New England Journal of Medicine. https://doi.org/10.1056/nejm200105103441904

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.